^
Association details:
Biomarker:KRAS G12C
Cancer:Solid Tumor
Drug:YL-17231 (pan-KRAS inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2627 / 11 - The small molecule KRAS inhibitor, TEB-17231, blocks tumor progression and overcomes KRASG12C inhibitor mediated resistance

Published date:
03/15/2023
Excerpt:
Further, TEB-17231 exhibited tumor growth inhibition (IC50) in KRAS-G12C Ba/F3 (14 nM) and derivative cell lines that acquired resistance to G12C inhibitor MRTX849….These properties highlight TEB-17231 as a potential clinically actionable inhibitor for the KRAS-modified tumor population